Nose to Brain Delivery: possibility or a pipedream?

Monday, October 17, 2022

10:30 AM – 11:30 AM ET

Location:360 Stage #1, Exhibit Hall A&B

Presented By

Partner Presentation Speaker(s)

Philip Kuehl, PhD

Senior Scientist
Lovelace Biomedical Research Institute
Albuquerque, New Mexico
Julie Suman, PhD

Vice President, Scientific Affairs
Aptar Pharma
Baltimore, Maryland

Nose to brain delivery continues to gain traction as a drug delivery platform. It currently includes nearly all drug classes and targets a wide range of indications. Throughout all phases of nose to brain development there are a range of in vitro and in vivo tools that can be used. However the strengths and weaknesses of each of these tools is not well understood. Therefore it can be difficult to manage risk for nose to brain drug development. In order to provide n understand of these tools and the current state of the art in nose to brain delivery this session will include two short (10 to 15 minutes each) presentations from experienced scientists from focused on the current nasal delivery landscape and the tools available for screening programs early on to reduce risk prior to advanced clinical trials. The remaining time will be a discussion (question and answer) around these topics which will include a wide range of experts. The expectation is that this session will support research scientists, development scientists, regulatory agencies and commercial teams as they determine the most appropriate approach for their program.

Learning Objectives:

Upon completion, participant will be able to have a complete understanding of the current landscape of intranasal drug delivery including nose to brain delivery.
Upon completion, participant will be able to have interacted directly with experts in intranasal drug delivery addressing their questions directly.
Upon completion, participant will be able to describe the strategies to remove risk from intranasal drug delivery early in their programs as they move towards clinical trials.